246 related articles for article (PubMed ID: 31099895)
1. Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Gravel S; Chiasson JL; Turgeon J; Grangeon A; Michaud V
Clin Pharmacol Ther; 2019 Dec; 106(6):1280-1289. PubMed ID: 31099895
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
3. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y
Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634
[TBL] [Abstract][Full Text] [Related]
5. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
6. Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently.
Duthaler U; Bachmann F; Suenderhauf C; Grandinetti T; Pfefferkorn F; Haschke M; Hruz P; Bouitbir J; Krähenbühl S
Clin Pharmacokinet; 2022 Jul; 61(7):1039-1055. PubMed ID: 35570253
[TBL] [Abstract][Full Text] [Related]
7. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
8. The effects of H2S on the activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in vivo in rat.
Wang X; Han A; Wen C; Chen M; Chen X; Yang X; Ma J; Lin G
Int J Mol Sci; 2013 Dec; 14(12):24055-63. PubMed ID: 24336065
[TBL] [Abstract][Full Text] [Related]
9. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
[TBL] [Abstract][Full Text] [Related]
11. Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.
Lin K; Zhang Q; Liu Z; Yang S; Lin Y; Wen C; Zheng Y
Int J Clin Exp Pathol; 2015; 8(5):5584-90. PubMed ID: 26191268
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.
Gravel S; Chiasson JL; Dallaire S; Turgeon J; Michaud V
BMJ Open; 2018 Feb; 8(2):e020922. PubMed ID: 29439084
[TBL] [Abstract][Full Text] [Related]
13. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?
Gazzaz M; Kinzig M; Schaeffeler E; Jübner M; Hsin CH; Li X; Taubert M; Trueck C; Iltgen-Breburda J; Kraus D; Queckenberg C; Stoffel M; Schwab M; Sörgel F; Fuhr U
Clin Pharmacol Ther; 2018 Dec; 104(6):1249-1259. PubMed ID: 29633238
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R; Jager Vd; Dawson R; Diacon AH; Narunsky K; Padayachee SD; Boeree MJ; van Beek SW; Colbers A; Coenen MJH; Svensson EM; Fuhr U; Phillips PPJ; Te Brake LHM; Aarnoutse RE;
Antimicrob Agents Chemother; 2023 Oct; 67(10):e0068323. PubMed ID: 37768317
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
16. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
[TBL] [Abstract][Full Text] [Related]
17. Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers.
Yi S; Cho JY; Lim KS; Kim KP; Kim J; Kim BH; Hong JH; Jang IJ; Shin SG; Yu KS
Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):249-56. PubMed ID: 19422358
[TBL] [Abstract][Full Text] [Related]
18. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
[TBL] [Abstract][Full Text] [Related]
19. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.
Kvitne KE; Åsberg A; Johnson LK; Wegler C; Hertel JK; Artursson P; Karlsson C; Andersson S; Sandbu R; Skovlund E; Christensen H; Jansson-Löfmark R; Hjelmesaeth J; Robertsen I
Clin Transl Sci; 2022 Nov; 15(11):2685-2696. PubMed ID: 36037309
[TBL] [Abstract][Full Text] [Related]
20. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
